Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The European Clinical Congress of Microbiology and Infectious Diseases (ECCMID 2019)

Select coverage from The European Clinical Congress of Microbiology and Infectious Diseases (ECCMID 2019) is included below:

Nicole Cotroneo, BS, on the Potential of Tebipenem to Treat Multidrug-Resistant UTIs
Nicole Cotroneo, BS, discusses her research presented at ECCMID 2019 on the activity of tebipenem against multidrug-resistant urinary tract infection-causing pathogens.
Novel Curative Strategy for HIV
Ben Berkhout, MD, PhD, discusses his work on the development of a novel curative strategy for HIV-1 infected individuals.
Takeaways from ECCMID 2019: Part 1
Experts from the fields of microbiology and infectious disease share their biggest takeaways and highlights from ECCMID 2019.
<i>Escherichia coli</i> ST131: Prevalence, Resistance, and Virulence in Boston vs Minneapolis
Elizabeth Hirsch, PharmD, and Mélanie Mahoney, PharmD candidate, discuss their poster on Escherichia coli ST131 in Boston vs Minneapolis at ECCMID 2019.
Developing New Options for Antibiotic-Resistant Gram-Negative Bacteria
Marin Kollef, MD, discusses recently approved agents targeting antibiotic resistant gram-negative bacteria and what to expect in the next 5 years.
Corrine Maurice, PhD: The Role of the Gut Microbiota
Corrine Maurice, PhD, discusses her talk at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID 2019) on the interactions between host, bacteria, gut microbiota, and bacteriophages.
Ben Berkhout, PhD: CRISPR-Cas Based Therapy for HIV
Ben Berkhout, PhD, discusses if CRISPR/Cas9 will be a new antiviral strategy for the eradication of HIV.
Top 5 Key Takeaways from ECCMID 2019
Here are the top takeaways from the European Congress of Clinical Microbiology and Infectious Disease 2019 meeting.
FEATURED
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?